drugset / Trial / NCT02112032
Treatment of Advanced Melanoma With MK-3475 and Peginterferon
Phase 1
Completed
43 enrolled
Hassane M. Zarour, MD
Melanoma Research Alliance · collabMerck Sharp & Dohme LLC · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is to test how safe it is to give the combination of PEG IFN-α2b (SYLATRON) and MK-3475, an investigational drug, to patients with advanced melanoma. Its effectiveness against melanoma will also be evaluated.
Timeline
- Start
- 2014-07-24
- Primary completion
- 2019-04-12
- Completion
- 2020-07-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peginterferon alfa-2b | Protein / enzyme biologic | 1 ug/kg | Subcutaneous |
| Subject | Peginterferon alfa-2b | Protein / enzyme biologic | 2 ug/kg | Subcutaneous |
| Subject | Peginterferon alfa-2b | Protein / enzyme biologic | 3 ug/kg | Subcutaneous |
| Subject | Pembrolizumab | Monoclonal antibody | 2 mg/kg | Intravenous |